Comparison of Efficacy and Safety of Fondaparinux and FraxiParine in Patients with Unstable Angina or Myocardial Infarction without ST-segment Elevation in China.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 08 Aug 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Fondaparinux sodium (Primary) ; Nadroparin calcium (Primary)
Indications Acute coronary syndromes; Embolism and thrombosis; Myocardial infarction; Unstable angina pectoris
Focus Adverse reactions; Therapeutic Use

21 May 2012 Actual end date 30 Apr 2010 added as reported by Chinese Clinical Trial Register.
01 Mar 2011 Status changed from recruiting to competed, as reported in the Chinese Medial Journal.
01 Mar 2011 Primary endpoint 'Myocardial-infarction-event-rate' has not been met.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com